Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study
Findings indicate dose-dependent real-world effectiveness of antipsychotics in CIP, with most agents performing best at 0.6-<1.4 DDDs/day. These results support optimizing dosing of oral antipsychotic medications for relapse prevention after CIP to balance efficacy and adverse effects.
Authors
- Solja Niemelä (ORCID: https://orcid.org/0000-0003-1130-9161)
- Ellenor Mittendorfer‐Rutz (ORCID: https://orcid.org/0000-0001-5227-0721)
- Heidi T. Taipale (ORCID: https://orcid.org/0000-0002-3281-934X)
- Antti Mustonen (ORCID: https://orcid.org/0000-0002-3259-2122)
- Jari Tiihonen
- Alexander Denissoff
- Marta Di Forti
- Antti Tanskanen
Institutions
- Seinäjoki University of Applied Sciences (FI)
- University of Eastern Finland (FI)
- South London and Maudsley NHS Foundation Trust (GB)
- Niuvanniemi Hospital (FI)
- Turku University Hospital (FI)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Psychiatry Research
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1016/j.psychres.2026.116966
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00